Showing 1213 results
- Media Release /China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is…
- Media Release /Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy …
- Media Release /Acquisition will give Novartis one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system Selective inhibition of the NLRP3…
- Key Release /Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients…
- Key Release /Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange…
- Media Release /Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire…
- Media Release /Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019…
- Key Release /Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced…
- Media Release /Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and…
- Media Release /New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16…